We are live on ! Find out more
Enavate Sciences

Enavate Sciences Portfolio holdings

AUM $345M Turnover 0%
1-Year Est. Return 134.64%
This Fund
S&P 500
This Quarter Est. Return
+6.06%
1 Year Est. Return
+134.64%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$345M
AUM Growth
-$6.13M
Cap. Flow
-$3.3M
Cap. Flow %
-0.96%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
–
Avg Time Held
1.4 years
Top 10 Avg Time Held
1.4 years
Top 20 Avg Time Held
1.4 years

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CAMP icon
CAMP4 Therapeutics
CAMP
+$3.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SION icon
1
Sionna Therapeutics
SION
$175M
$109M 31.56%
2,478,030
– –
2025 Q1
5 quarters
ZBIO icon
2
Zenas BioPharma
ZBIO
$1.85B
$99.5M 28.8%
3,919,159
– –
2024 Q4
6 quarters
IMNM icon
3
Immunome
IMNM
$2.15B
$76.6M 22.17%
3,613,799
– –
2024 Q4
6 quarters
BBOT icon
4
BridgeBio Oncology
BBOT
$210M
$20M 5.8%
2,626,946
– –
2025 Q3
3 quarters
CMPX icon
5
Compass Therapeutics
CMPX
$142M
$17.1M 4.94%
7,788,150
– –
2024 Q4
6 quarters
UPB icon
6
Upstream Bio Inc
UPB
$187M
$17M 4.93%
2,459,703
– –
2024 Q4
6 quarters
CAMP icon
7
CAMP4 Therapeutics
CAMP
$249M
$6.23M 1.8%
1,425,541
-765,379
-35% -$3.3M
2024 Q4
6 quarters

Similar funds

LCM
Lonestar Capital Management San Francisco, California $345M AUM 80.24% 1-Year Est. Return
Matthew 25 Management Corp
Matthew 25 Management Corp Ambler, Pennsylvania $345M AUM 31.27% 1-Year Est. Return
Front Row Advisors
Front Row Advisors Tiburon, California $345M AUM 39.04% 1-Year Est. Return
Muhlenkamp & Co
Muhlenkamp & Co Wexford, Pennsylvania $345M AUM 34.25% 1-Year Est. Return
Bear Mountain Capital
Bear Mountain Capital Seattle, Washington $345M AUM 13.71% 1-Year Est. Return
RR Advisors
RR Advisors Dallas, Texas $346M AUM 31.14% 1-Year Est. Return
WFI
West Family Investments Carlsbad, California $345M AUM 46.29% 1-Year Est. Return
Sender Company & Partners
Sender Company & Partners New York $345M AUM 41.88% 1-Year Est. Return

Enavate Sciences's Q2 2026 Portfolio in Review

As of Q2 2026, Enavate Sciences held 7 positions worth $345M, down 1.7% from $352M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2026: portfolio turnover was 0%. Enavate Sciences opened no new positions and made no exits, leaving the 7-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Enavate Sciences's biggest Q2 2026 reduction was CAMP4 Therapeutics, cutting an estimated $3.3M.
  • Enavate Sciences's ten largest holdings make up 100% of its $345M portfolio in Q2 2026.
  • Enavate Sciences opened 0 new positions and closed 0 in Q2 2026.
  • Enavate Sciences's portfolio value fell 1.7% quarter-over-quarter to $345M.

Based on Enavate Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.